title: [INTERLEUKIN 1 INHIBITORS--A NEW HORIZON IN THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER].
abstract: Familial Mediterranean Fever (FMF) is a common genetic auto-inflammatory disease in the Middle Eastern population. Colchicine is the only proven treatment for the prevention of FMF attacks and reactive amyloidosis. However, 5-10% of FMF patients do not respond to colchicine, and an additional 5% are intolerant to it. Progress in the understanding of FMF and the recognition of the central role of IL-1 in its pathophysiology has led to the introduction of IL-1 inhibitors in FMF patients who are unresponsive to colchicine. In this paperwe review the clinical experience gained with IL-1 inhibitors in FMF. Overall, it appears that IL-1 inhibitors are safe and may serve as an alternative in FMF patients resistant to colchicine.
authors.forename: Roni
authors.initials: R
authors.lastname: Shouval
authors.forename: Avi
authors.initials: A
authors.lastname: Livneh
authors.forename: Ilan
authors.initials: I
authors.lastname: Ben-Zvi
mesh_terms: D003078:Colchicine / Q000627:therapeutic use; D010505:Familial Mediterranean Fever / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D007375:Interleukin-1; D003078:Colchicine